Eyeworld Daily News

2022 EyeWorld Daily News Friday

EyeWorld Today is the official daily of the ASCRS Symposium & Congress. Each issue provides comprehensive coverage editorial coverage of meeting presentations, events, and breaking news

Issue link: https://daily.eyeworld.org/i/1465478

Contents of this Issue

Navigation

Page 26 of 74

24 | EYEWORLD DAILY NEWS | APRIL 22, 2022 ASCRS ANNUAL MEETING DAILY NEWS BAK can be used in the drug, but the hydrogel traps the preservative so the drop can go into the eye preserva- tive free. He noted there are several products in development with this technology, including one with lata- noprost and a brimonidine/timolol combination, both currently planned for launch in 2024. ViaLase Tibor Juhasz, PhD, spoke about ViaLase and its OCT image-guided femtosecond laser trabeculotomy. It reduces IOP by increasing aqueous outflow using a micron resolution 3-D image-guided femtosecond laser to non-invasively create customized drainage channels through the trabecular meshwork in the vicinity of collector channels. Dr. Juhasz said it showed excellent IOP reduction through 19 months, and he said results compared favorably to all other trabecular outflow technologies. He also noted that there were no signs of scarring or channel closure noticed at 12 months. Eyenovia Sean Ianchulev, MD, shared infor- mation on the Optejet, which aims to provide a better design for patient delivery of eye drops. This patient-cen- tric design, he said, delivers a dose of 7–9 microliters, which matches the tear film capacity. The horizontal, gentle spray helps eliminate the need for head tilting, and the "no touch" system with a recessed nozzle minimizes contami- nation opportunities, he said. Optejet also features onboard, smart technolo- gy that allows for dosage tracking and reminders. The built-in monitoring can aid with compliance. Dr. Ianchulev also stressed the microdosing aspect, and he added that it had good tolerability in trials. Editors' note: The presenters have financial interests with a variety of ophthalmic companies. this is an inside-the-eye NSAID, which offers controlled release, avoids topical side effects, guarantees compliance, and enhances patient satisfaction. The OcuRing-K aims to improve the thera- peutic index of an NSAID. Dr. Mandell discussed the Phase 1 study. One of the most important things, he said, was that OcuRing-K implantation was shown to be compatible with standard surgery technique. Results further found the IOL and OcuRing-K to be positioned properly with no move- ment or contact with adjacent tissues. The eye was clear with no evidence of inflammation. Dr. Mandell added that no steroids were given in the protocol, and none were used as rescue therapy. ForSight VISION6 Ayman Naseri, MD, spoke about the Opira accommodating lens. This prod- uct, he said, is a ciliary muscle-driven, capsule-fixated, dynamic, shape-chang- ing IOL. It has direct ciliary body engagement without zonular or capsular bag intermediaries. It's haptic fixated within the capsulorhexis. Dr. Naseri noted early clinical results of 32 patients at 6 months, which found uncorrected distance vision better than 20/20, intermediate at 20/20, and 20/25 at near. The Opira AIOL has excellent long-term safety and stability, he said, with excellent visual acuity and refractive outcomes. It provides continuous "monofocal quality" vision across functional near range. Glaucoma spotlight TearClear William Wiley, MD, presented on the TearClear, which he said offers the most effective use of preservatives. BAK is the gold standard preservative for multidose and helps ensure safety, stability, and solubility. However, it damages the ocular surface, causes increased inflammation, and reduces surgical success. TearClear, he said, helps provide the best of both worlds with a bottle with a hydrogel tip. The T he Eyecelerator program featured spotlight sessions on cataract and glaucoma. Cataract spotlight Beyeonics Vision Miles Harper shared information on Beyeonics One, the first ophthalmic exoscope with an augmented reality (AR) surgical headset. Mr. Harper said the AR surgical headset is lightweight and comfortable, has an immersive natural feeling, and head gesture control. There have been some recent improvements to the product's design. Mr. Harper specifically noted being able to switch between viewing the surgical field then to seeing the patient. A new camera lens helps improve im- age quality. The Beyeonics One offers surgical freedom and a natural pose, he said. There are also teaching features with the device. Centricity Todd Pinkney spoke about ZEPTO, noting recent innovations. A new console was launched a few months ago, which offers improved safety, centered capsulotomies, and 360-de- gree overlap. This has been used by 28 current and new users in more than 700 cases with a 100% success rate, he said. ZEPTO offers centered capsu- lotomies, and there is consistency in shape and size. It also has significantly lower capital equipment and procedur- al costs versus femto and works well for complex cases. Centricity plans to offer a larger size for surgeons wanting a slightly larger opening. Mr. Pinkney also discussed the latest innovation, ZEPTOLINK, which integrates with any phacoemulsification system. This streamlines cataract surgery and pro- vides complete control via the phaco foot pedal, he said. LayerBio Kenneth Mandell, MD, PhD, shared information on the OcuRing-K. He said Spotlight sessions at Eyecelerator highlight cataract and glaucoma topics

Articles in this issue

Archives of this issue

view archives of Eyeworld Daily News - 2022 EyeWorld Daily News Friday